Equities Research Analysts’ Updated EPS Estimates for June 16th (ACLX, ANGI, BTDR, CAN, CGNX, COIN, CRWV, CTLP, GOVX, IIIV)

Equities Research Analysts’ updated eps estimates for Monday, June 16th:

Arcellx (NASDAQ:ACLX) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $115.00 price target on the stock.

Angi (NASDAQ:ANGI) was downgraded by analysts at Citizens Jmp from an outperform rating to a market perform rating.

Angi (NASDAQ:ANGI) had its market perform rating reissued by analysts at JMP Securities.

Bitdeer Technologies Group (NASDAQ:BTDR) had its buy rating reiterated by analysts at Rosenblatt Securities. They currently have a $20.00 price target on the stock.

Canaan (NASDAQ:CAN) had its buy rating reissued by analysts at Rosenblatt Securities. The firm currently has a $5.00 price target on the stock.

Cognex (NASDAQ:CGNX) had its neutral rating reissued by analysts at DA Davidson. They currently have a $32.00 price target on the stock.

Coinbase Global (NASDAQ:COIN) had its buy rating reiterated by analysts at Rosenblatt Securities. The firm currently has a $300.00 price target on the stock.

CoreWeave, Inc. Class A Common Stock (NASDAQ:CRWV) was downgraded by analysts at Bank of America Co. from a buy rating to a neutral rating.

Cantaloupe (NASDAQ:CTLP) was downgraded by analysts at William Blair from an outperform rating to a market perform rating.

GeoVax Labs (NASDAQ:GOVX) had its buy rating reiterated by analysts at D. Boral Capital. The firm currently has a $9.00 price target on the stock.

i3 Verticals (NASDAQ:IIIV) had its buy rating reissued by analysts at Benchmark Co.. They currently have a $33.00 target price on the stock.

IMAX (NYSE:IMAX) had its buy rating reaffirmed by analysts at Rosenblatt Securities. Rosenblatt Securities currently has a $35.00 price target on the stock.

Innodata (NASDAQ:INOD) had its buy rating reiterated by analysts at BWS Financial. They currently have a $74.00 target price on the stock.

Disc Medicine (NASDAQ:IRON) had its outperform rating reiterated by analysts at Wedbush. Wedbush currently has a $90.00 target price on the stock.

Intellia Therapeutics (NASDAQ:NTLA) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $30.00 target price on the stock.

Intellia Therapeutics (NASDAQ:NTLA) had its neutral rating reissued by analysts at Wedbush. Wedbush currently has a $7.00 target price on the stock.

Ohmyhome (NASDAQ:OMH) had its hold rating reissued by analysts at Maxim Group.

Packaging Co. of America (NYSE:PKG) was downgraded by analysts at Jefferies Financial Group Inc. from a buy rating to a hold rating. Jefferies Financial Group Inc. currently has $205.00 target price on the stock, down from their previous target price of $245.00.

PROS (NYSE:PRO) was downgraded by analysts at Robert W. Baird from an outperform rating to a neutral rating. Robert W. Baird currently has $18.00 price target on the stock, down from their previous price target of $27.00.

Roku (NASDAQ:ROKU) had its outperform rating reiterated by analysts at Wedbush. The firm currently has a $100.00 price target on the stock.

Sage Therapeutics (NASDAQ:SAGE) had its hold rating reissued by analysts at Needham & Company LLC.

Shell (NYSE:SHEL) was downgraded by analysts at Sanford C. Bernstein from an outperform rating to a market perform rating.

Sarepta Therapeutics (NASDAQ:SRPT) had its neutral rating reaffirmed by analysts at Bank of America Co..

Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by analysts at Cantor Fitzgerald from an overweight rating to a neutral rating.

Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by analysts at Piper Sandler from an overweight rating to a neutral rating. Piper Sandler currently has $36.00 price target on the stock, down from their previous price target of $70.00.

Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by analysts at HC Wainwright from a neutral rating to a sell rating.

Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by analysts at BMO Capital Markets from an outperform rating to a market perform rating. The firm currently has $70.00 target price on the stock.

Vericel (NASDAQ:VCEL) had its overweight rating reiterated by analysts at Stephens. The firm currently has a $67.00 price target on the stock.

VEON (NASDAQ:VEON) had its buy rating reiterated by analysts at Benchmark Co.. Benchmark Co. currently has a $60.00 price target on the stock.